by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
Australian Journal of Pharmacy : March 2005
Nurofen solution Marketing director at Boots Healthcare Australia, Jenny Shortall commented: ‘Boots Healthcare Australia is proud to be in partnership with Headache Australia to produce this brochure. Our leading brand, Nurofen, continues to strengthen and is the number one adult analgesic in pharmacy with a value share of more than 28 per cent, delivering more than $1m in scan sales to pharmacy every week.’3 With Nurofen, customers can be offered relief from a range of headaches, including those caused by stress, sinus, tension and eyestrain. And, as well as being useful for a range of headaches, Nurofen is fast- acting*,4,5 tolerated.6 effective and well But customers aren’t the only ones who can benefit from Nurofen. By recommending Nurofen for headache, pharmacists can enjoy the loyalty of customers who keep coming back for good advice. For more information on headache visit the Headache Australia website at: www.headacheaustralia.org.au or call the Headache Australia information line on 1300 886 660. For copies of the Understanding Headache brochures call the Nurofen enquiries line (freecall) 1800 226 766. NUROFEN MIGRAINE Nurofen Migraine is ibuprofen lysine 342mg— equivalent to ibuprofen 200mg. Ibuprofen lysine is a salt of ibuprofen that dissolves quickly and is absorbed fast into the bloodstream to bring fast relief from migraine pain. Fast relief is an important benefit for the treatment of migraine. When a migraine sufferer senses a migraine coming on, they need to act quickly. If they delay taking pain relief, the ability of their stomach to absorb medicine is reduced, so the migraine pain reliever they take is less likely to be effective. By taking Nurofen Migraine at the first onset of symptoms, further development of migraine pain can be prevented. Nurofen Migraine also meets the consumer need for a migraine-specific analgesic. Nurofen Migraine Pain is the first OTC migraine-specific analgesic to be launched in Australia. WHAT, STOP, GO—Protocols for pharmacy and pharmacist-only medicines* WHAT: Determine what is wrong and assess the customer’s current medicines and health status 1. Who is the patient? 2. How long have symptoms been present? 3. Actual symptoms—what are they? 4. Treatment for this or any other condition? STOP: Stop and assess the situation 1. Symptoms or side effects caused by other conditions and/or medicines? 2. Totally sure—any special patient needs or circumstances? *Ibuprofen 400mg. 1. Newspoll Market Research, ‘Headache Study,’ (1200 respondents aged 18 and over), August 2004. 2. Headache Disorders and Public Health - Education and Management Implications, World Health Organisation, September 2000 (WHO/MSD/MBD/009) p3. 3. Source: AZTEC Value 4 weeks Dec 04. 4. Schachtel BP, Thoden WR. Headache Journal, August 1988; 28: 471–4. 5. Broome JR, et al.Aviat Space Environ Med, 1994; 65: 19–20. 6. Moore N et al. Clin Drug Invest 1999; 18 (2) 89–98. 3. Overuse/abuse—how often has the patient been taking the medicine or self-treating the condition? 4. Pharmacist Only—always refer to the pharmacist. Check whether the patient would like to speak with the pharmacist. GO: Supply medicine if appropriate and provide advice 1. Ask the patient if they have any further questions. Would the patient like a CMI for the pharmacist-only medicine? Provide advice on how to use the medicine. * Developed by the Pharmaceutical Society of Australia as a tool to help meet the Standards for the Provision of Pharmacy and Pharmacist-Only Medicines in Community Pharmacy (1999). Nurofen is a registered Trademark. Nurofen contains ibuprofen 200mg. Boots Healthcare Australia Pty Ltd. ACN 000 071 278. 101 Waterloo Road, North Ryde NSW 2113. THE AUSTRALIAN JOURNAL OF PHARMACY VOL 86 MARCH 2005 ? 155